PharmaMar Announces Participation at the 17th Needham & Co Annual Healthcare Conference in New York City

MADRID, March 26, 2018 /PRNewswire/ --

PharmaMar (MCE: PHM), today announced it will be featured as a presenting company at the 17th Needham & Co Annual Healthcare Conference. The conference is being held on March 27-28 at the Westin New York Grand Central hotel in New York, NY.

     (Logo: http://mma.prnewswire.com/media/624563/PharmaMar_Logo.jpg )

Pascal Besman, Chief Operating Officer, and Jose Luis Moreno, Director of Capital Markets, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event: Needham & Co Annual Healthcare Conference

Date: March 27

Time: 2:30PM (ET)

Location: Westin New York Grand Central hotel in New York, NY

The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/needham86/phm.mc/ The webcast replay will remain available for 90 days following the live presentation. 

About PharmaMar  

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS^® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.

Contact information:

Media Relations
+34-638-796-215

Investor Relations
+34-914-444-500

SOURCE PharmaMar